For research use only. Not for therapeutic Use.
Tucotuzumab（Cat No.:I042250）is a monoclonal antibody designed to target and inhibit the receptor CD47, a “don’t eat me” signal expressed on the surface of cancer cells. CD47 prevents the immune system, particularly macrophages, from recognizing and engulfing cancer cells. By blocking this interaction, Tucotuzumab promotes immune system activation and enhances the body’s ability to target and eliminate cancer cells. It has shown potential in clinical trials for treating various cancers, including leukemia and solid tumors. Ongoing research is focused on evaluating Tucotuzumab’s efficacy, safety, and potential as a treatment option in cancer immunotherapy.
| Catalog Number | I042250 |
| CAS Number | 339986-90-2 |
| Purity | ≥95% |
